2024. Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s477. DOI:https://doi.org/10.25251/skin.8.supp.477.